Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | RBP4 | P02753 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | ME2 | P23368 | 1/20 | 0.52 |
| ▸ | ME1 | P48163 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060746 | 0.87 | MAPT (0.56) | HCAR2KDM4EMAPTMAPK1KMT2A | |
| SCHEMBL29178292 | 0.80 | LMNA (0.75) | MAPTCYP2C19MAPK1KMT2ALMNA | |
| SCHEMBL13666087 | 0.79 | HCAR2 (1.00) | HCAR2KDM4EMAPTMAPK1KMT2A | |
| SCHEMBL20291070 | 0.77 | CA12 (0.74) | LMNAHTTNAMPTME2ME1 | |
| SCHEMBL22581768 | 0.77 | CA12 (0.74) | LMNAHTTNAMPTME2ME1 | |
| SCHEMBL16690819 | 0.76 | TRPV1 (0.66) | HCAR2KDM4ERBP4CYP2D6CYP2C19 | |
| SCHEMBL13666089 | 0.74 | HCAR2 (0.75) | HCAR2KDM4EMAPTMAPK1KMT2A | |
| SCHEMBL16690826 | 0.74 | HCAR2 (0.57) | HCAR2KDM4ERBP4CYP2D6CYP2C19 | |
| SCHEMBL29178274 | 0.74 | CA12 (0.53) | MAPTMAPK1KMT2ALMNAHTT | |
| SCHEMBL22581849 | 0.74 | DEGS1 (0.56) | MAPTLMNAHTTNAMPTME2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | SMITHKLINE BEECHAM CORPORATION | 2008-06-12 | — | — | US | claimed |
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | SMITHKLINE BEECHAM CORPORATION | 2008-06-12 | — | — | US | disclosed |
| EP-1848707-A1 | AWTHRANILIC ACID DERIVATIVES AND THEIR USE IN TREATMENT OF DISEASES OF LIPID METABOLISM, IN PARTICULAR DYSLIPIDAEMIA | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006085108-A1 | AWTHRANILIC ACID DERIVATIVES AND THEIR USE IN TREATMENT OF DISEASES OF LIPID METABOLISM, IN PARTICULAR DYSLIPIDAEMIA | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | ANTXR2, CYP46A1, HCAR1 | HCAR2 16/4885KDM4E 3897/4885MAPT 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.